Apimeds Pharmaceuticals US (APUS) Share-based Compensation (2025)

Apimeds Pharmaceuticals US (APUS) reported Share-based Compensation of $1.8 million for Q4 2025, up 4140.19% quarter-over-quarter from $42674.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Share-based Compensation (2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Share-based Compensation for 1 years, with the latest figure at $1.8 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 43.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 25.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 33.90 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -395,114.54
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 57.20 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 21.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 36.33 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 36.86 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 16.04 Mn
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn - 1.81 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 1.81 Mn
Dec 31, 2025 1.81 Mn
Sep 30, 2025 42,674.00
Sep 30, 2025 42,674.00
Jun 30, 2025 178,424.00
Jun 30, 2025 178,424.00